Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis: Better Margin Visibility Ex-Sandoz
12:48am, Friday, 06'th Oct 2023
Ex-Sandoz, Novartis confirmed its yearly guidance and capital allocation priority (DPS growth and buyback). We believe NVS might experience a margin uplift following the spin-off. Sandoz started tradi
Basel, October 5, 2023 — Novartis will present new data from 29 Novartis and investigator-led abstracts at the European Society for Medical Oncology (ESMO) Congress 2023, highlighting latest develop
Novartis (NVS) Spins off Sandoz, Reiterates Annual Outlook
01:31pm, Wednesday, 04'th Oct 2023
Novartis (NVS) separates Sandoz into an independent company. The company reaffirms the previously provided guidance.
SDZNY Stock: 7 Things to Know as Novartis Spinoff Sandoz Starts Trading Today
11:33am, Wednesday, 04'th Oct 2023
Sandoz (OTCMKT: SDZNY ) stock is a hot topic among traders on Wednesday as the company starts trading after a spinoff. Let's get into everything investors need to know about Sandoz below!
Novartis spin-off completed as Sandoz makes subdued start on Swiss bourse
07:13am, Wednesday, 04'th Oct 2023
Swiss drugs giant Novartis AG has completed the spin-off of its generics business Sandoz, which made an underpowered stock market debut. From an IPO price of 24 Swiss Francs, the stock drifted down t
Novartis unit Sandoz set to start trading after completing spinoff
01:51am, Wednesday, 04'th Oct 2023
Novartis has completed the planned spin-off of its generics and biosimilars business, Sandoz, which will begin trading on the SIX Swiss Exchange on Wednesday.
Novartis completes Sandoz spinoff
01:20am, Wednesday, 04'th Oct 2023
Novartis has completed the planned spin-off of its generics and biosimilars business Sandoz , the Swiss drugmaker said in a statement on Wednesday.
Novartis (NVS) Announces Positive Data on Kidney Disease Drug
01:32pm, Tuesday, 03'rd Oct 2023
Novartis' (NVS) phase III study on pipeline candidate iptacopan in patients with IgAN shows superiority versus placebo in proteinuria reduction.
Novartis positioning is now best-suited for long-term gains and returns after spin-off, says CEO
12:08pm, Tuesday, 03'rd Oct 2023
Novartis CEO Vas Narasimhan joins 'Squawk on the Street' to discuss the company's new spin-off Sandoz, what a pure-play core pharmaceutical company means, and the idea of M&A to boost the company's gr
Novartis CEO: Company set to become a pure play, innovative medicine business after Sandoz spin off
11:26am, Tuesday, 03'rd Oct 2023
Vas Narasimhan, CEO at Novartis, discusses the company's 100% spin off of Sandoz, its generic and biosimilar medicines business, and what the deal means for shareholders.
Here's Why Novartis (NVS) is a Strong Value Stock
11:17am, Tuesday, 03'rd Oct 2023
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novartis considers selling radiopharma unit's assets - Bloomberg News
10:16am, Tuesday, 03'rd Oct 2023
Novartis AG is considering selling a part of its radiopharmaceuticals business, Bloomberg News reported on Tuesday, citing people with knowledge of the matter.
Drugmakers opt in to Medicare drug price negotiations – here's what happens next
03:34pm, Monday, 02'nd Oct 2023
The lengthy negotiation process with Medicare won't end until August 2024, with reduced prices going into effect in January 2026.
Drugmakers sign on to negotiate Medicare prices under protest
01:02pm, Monday, 02'nd Oct 2023
All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis , said they signed on to part
Novartis' (NVS) Sandoz Gets EC Nod for Tysabri's Biosimilar
01:31pm, Tuesday, 26'th Sep 2023
Novartis' (NVS) Sandoz broadens its biosimilar portfolio with Tyruko's approval, a biosimilar of the multiple sclerosis drug Tysabri in the EU.
